Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
Ardelyx, Inc. received a Schedule 13G filing from hedge fund–related entities reporting significant passive ownership of its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 12,855,317 shares, representing 5.3% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 13,121,781 shares, or 5.4% of the class, with shared voting and dispositive power and no sole authority. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Ardelyx, but instead are held on a passive basis.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an option exercise and share sale in Ardelyx common stock. On January 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $0.99 per share, then sold 50,000 shares at a weighted average price of $6.978 per share, with individual trades executed between $6.97 and $7.00.
After these transactions, Williams directly owned 361,563 shares of Ardelyx common stock, a figure that reflects an earlier purchase of 1,667 shares under the Ardelyx Employee Stock Purchase Plan in August 2025. She also held 62,000 stock options with a $0.99 exercise price, expiring on January 6, 2032, which vest in equal monthly installments that began in January 2022.
Ardelyx stockholder plans to sell shares under Rule 144. A notice was filed for the planned sale of 50,000 shares of Ardelyx common stock through Morgan Stanley Smith Barney LLC on or around 01/08/2026, listed with an aggregate market value of $291,500. The shares are to be sold on the NASDAQ, and the filing shows total Ardelyx shares outstanding of 242,974,306.
The 50,000 shares were acquired the same day, 01/08/2026, via a cash exercise of stock options granted by the issuer. The filing also reports that Laura A. Williams sold 6,426 Ardelyx common shares in a prior transaction on 11/21/2025 for gross proceeds of $35,580.12. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the company.
Ardelyx, Inc. reported preliminary, unaudited product sales for 2025. U.S. net product sales revenue of IBSRELA® (tenapanor) was approximately $87 million in the fourth quarter and approximately $274 million for the full year ended December 31, 2025. U.S. net product sales revenue of XPHOZAH® (tenapanor) was approximately $28 million in the fourth quarter and approximately $104 million for the full year.
The company also indicated it had approximately $265 million in cash, cash equivalents, and short-term investments as of December 31, 2025, on an unaudited basis. All figures are preliminary, may be adjusted during the audit process, and have not been audited or reviewed by Ernst & Young LLP.
Ardelyx, Inc. reported senior leadership changes effective December 31, 2025. Elizabeth Grammer resigned as Chief Legal and Administrative Officer, but will continue as General Counsel until a successor is named and then serve as a Senior Advisor for 24 months under a Transition and Separation Agreement. During an initial 12‑month employment period, she will keep her current base salary, remain eligible for an annual target bonus equal to 45% of base salary for 2025, and continue to receive senior non‑executive benefits, followed by a one‑month salary payment if she delivers a general release.
In the second 12 months, her equity will continue to vest, she may receive advisory payments for the first nine months, and Ardelyx will pay COBRA health premiums for her and dependents during the advisory term or until she gains other coverage. Separately, Chief Medical Officer Edward Conner, M.D. will resign for personal reasons, and Chief Patient Officer and former CMO Dr. Laura Williams will act as interim Chief Medical Officer, overseeing clinical development until a permanent replacement is hired.
Ardelyx, Inc. (ARDX) insider activity: Chief Legal and Administrative Officer Elizabeth Grammer reported a Form 4 transaction dated 11/21/2025. She sold 5,995 shares of Ardelyx common stock at a price of $5.5369 per share. The filing explains that the sale was an automatic sell-to-cover triggered by the vesting of restricted stock units, and the shares were sold solely to cover applicable withholding taxes.
After this transaction, she beneficially owns 299,895 shares of Ardelyx common stock directly.
Ardelyx, Inc. (ARDX) reported an insider stock sale by its president and CEO, who is also a director. On 11/21/2025, the executive sold 46,887 shares of common stock at $5.5369 per share. According to the filing, this sale was made under an automatic sell-to-cover feature tied to restricted stock unit (RSU) awards and was done solely to cover withholding taxes due at vesting.
After this transaction, the executive beneficially owns 1,455,363 shares of Ardelyx common stock directly. In addition, 24,364 shares are held in a living trust and 1,000 shares are held in trusts for the executive’s children, both reported as indirect ownership.
Ardelyx, Inc. (ARDX) reported an insider equity transaction by its Chief Business Officer, Mike Kelliher. On 11/21/2025, he sold 5,560 shares of common stock at a price of $5.5369 per share. The company states these shares were sold automatically upon the vesting of restricted stock units to cover applicable withholding taxes, rather than as a discretionary sale.
Following this transaction, Kelliher directly beneficially owns 271,181 shares of Ardelyx common stock. The filing is a Form 4 submitted for one reporting person and reflects a routine tax-related sale connected to equity compensation.
Ardelyx, Inc. (ARDX) reported an insider share sale by its Chief Patient Officer, Laura A. Williams. On 11/21/2025, Williams sold 6,426 shares of Ardelyx common stock at a price of $5.5369 per share. The filing explains that this was a sell-to-cover transaction imposed by the terms of the original restricted stock unit ("RSU") awards and that the shares were sold solely to cover applicable withholding taxes when the RSUs vested.
Following this tax-related sale, Williams beneficially owned 359,896 shares of Ardelyx common stock, held in direct ownership. The transaction was reported on a Form 4 filed for a single reporting person.
Ardelyx, Inc. (ARDX) reported a Form 4 filing for its Chief Commercial Officer, who is an officer but not a 10% owner. On 11/21/2025, the officer sold 5,814 shares of Ardelyx common stock at a price of $5.5369 per share. According to the explanation, the sale was an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover withholding taxes. Following this transaction, the officer directly beneficially owns 295,684 shares of Ardelyx common stock.